Skip to main content
main-content

01.11.2010 | Ausgabe 4/2010

Journal of Thrombosis and Thrombolysis 4/2010

Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay

Zeitschrift:
Journal of Thrombosis and Thrombolysis > Ausgabe 4/2010
Autoren:
In-Suk Kim, Young-Hoon Jeong, Min-Kyung Kang, Jin-Sin Koh, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim

Abstract

In vitro “high post-treatment platelet reactivity” (HPPR) measured with light transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay has been associated with an increased risk of ischemic events after percutaneous coronary intervention (PCI). However, there are many criteria for HPPR according to the methods used for assessment, and correlations among suggested criteria have not been evaluated. To this end, we enrolled 1,058 unselected patients undergoing PCI in real clinical practice, simultaneously assessed platelet measures with LTA (both 5 and 20 μmol/l ADP-induced) and the VerifyNow P2Y12 assay, and based on previous studies, evaluated the following criteria for HPPR: 5 or 20 μmol/l ADP-induced maximal platelet reactivity (PRmax) ≥50%; 5 μmol/l ADP-induced late PR (PRlate) >14%; 20 μmol/l ADP-induced PRmax ≥62%; and P2Y12 reaction unit (PRU) ≥240. Receiver-operating characteristics (ROC) curve analysis demonstrated that PRU (cut-off = 241) distinguished between patients with and without 5 μmol/l ADP-induced PRmax ≥50% (area under curve [AUC] 0.822, sensitivity 83.0%, specificity 66.0%, P < 0.001), and 20 μmol/l ADP-induced PRmax ≥62% (AUC 0.840, sensitivity 80.7%, specificity 71.4%, P < 0.001), respectively. PRU ≥240 showed a moderate agreement with 5 μmol/l ADP-induced PRmax ≥50% (κ = 0.438, concordant rate 71.6%, P < 0.001) and 20 μmol/l ADP-induced PRmax ≥62% (κ = 0.505, concordant rate 75.1%, P < 0.001). Cut-offs matched for 20 μmol/l ADP-induced PRmax ≥50% (PRU = 195) and 5 μmol/l ADP-induced PRlate >14 (PRU = 194) also were similar. The presence of significant correlations between the suggested criteria for HPPR has practical implications on the possible use of the VerifyNow P2Y12 assay for risk stratification in PCI-treated patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2010

Journal of Thrombosis and Thrombolysis 4/2010 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise